top of page


AbTherx licenses Atlas antibody discovery platform to Athenova for targeted alpha cancer therapies
Athenova will use AbTherx's fully human antibody discovery technology for astatine-211 radiopharmaceutical programmes under a licensing agreement involving research payments, milestones and royalties.

nuaxia
5 hours ago2 min read


Piramal Pharma moves to acquire remaining 26% of biologics CDMO Yapan Bio
The proposed purchase would increase Piramal Pharma's ownership of the vaccines and biologics CDMO from 74% to 100%, with final consideration and completion terms still under discussion.

nuaxia
5 hours ago2 min read


AbbVie signs $2.54 billion potential oncology collaboration with DISCO Pharmaceuticals for AND-gated bispecifics
AbbVie will combine its oncology development expertise with DISCO's tumour-surface mapping technology to discover selective bispecific therapies, with $40 million payable upfront and further potential milestones.

nuaxia
5 hours ago2 min read


Arcturus expands Meiji Seika Pharma partnership with $50 million investment and new mRNA licence
Meiji Seika Pharma has committed $50 million to Arcturus Therapeutics and expanded their mRNA technology partnership through a new licence, strengthening collaboration on RNA medicines and potential pandemic preparedness.

nuaxia
1 day ago2 min read


Pfizer licenses Starna Therapeutics' in vivo CAR-T programmes in deal worth up to $2.63 billion
Pfizer has secured rights to three preclinical in vivo CAR-T programmes from Starna Therapeutics through a licensing agreement featuring $330 million upfront and up to $2.3 billion in contingent milestone payments.

nuaxia
1 day ago2 min read


Thermosome grants Avenor global licence to heat-activated oncology platform and Phase II-ready THE001
Thermosome has granted Avenor Therapeutics exclusive worldwide rights to its heat-activated oncology drug-delivery platform and Phase II-ready THE001 candidate, supporting a combined drug and hyperthermia development strategy.

nuaxia
2 days ago1 min read


Eli Lilly signs oncology research partnership with Stipple Bio carrying up to $5.9 billion in potential milestones
Eli Lilly has entered a multi-target oncology research collaboration with Stipple Bio carrying up to $5.9 billion in potential milestone payments, centred on the discovery of tumour-specific therapeutic targets.

nuaxia
2 days ago1 min read


Eli Lilly agrees to acquire Calytrix Bio for up to $1.5 billion to expand rare blood cancer pipeline
Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion, adding a preclinical antibody programme targeting mutant calreticulin in rare myeloproliferative blood disorders.

nuaxia
3 days ago2 min read


Johnson & Johnson agrees to acquire Ollin Biosciences for up to $3.3 billion to expand retinal disease pipeline
Johnson & Johnson has agreed to acquire ophthalmology biotechnology company Ollin Biosciences for up to approximately $3.3 billion, adding a Phase III retinal disease antibody programme alongside a separate $750 million Blackstone development funding arrangement.

nuaxia
3 days ago2 min read


OBI Pharma signs ADC platform licensing agreement with Novartis worth more than $2 billion
OBI Pharma has entered a global antibody-drug conjugate platform licensing agreement with Novartis carrying more than $2 billion in potential value, including a $30 million upfront payment and additional contingent milestones and royalties.

nuaxia
4 days ago2 min read


Pfizer and Blackstone agree up to $1.5 billion in development funding for monthly GLP-1 obesity candidate berobenatide
Pfizer and Blackstone Life Sciences have agreed a development co-funding arrangement of up to $1.5 billion for investigational once-monthly GLP-1 therapy berobenatide, sharing clinical development risk while Pfizer retains control of the programme.

nuaxia
Nov 132 min read


PharmaLogic agrees to acquire Lantheus radiopharmaceutical CDMO business and New Jersey manufacturing facility
PharmaLogic has signed a definitive agreement to acquire Lantheus' radiopharmaceutical CDMO operations and Springfield manufacturing facility, expanding specialist production capabilities for therapeutic radiopharmaceuticals.

nuaxia
Nov 132 min read


Edesa Biotech licenses paridiprubart to Kyorin in Japan for up to $146 million plus royalties
Edesa Biotech has licensed Japanese development and commercialisation rights to its investigational anti-TLR4 antibody paridiprubart to Kyorin Pharmaceutical in an agreement worth up to $146 million in stated payments plus royalties.

nuaxia
Nov 112 min read


Third Rock Ventures signs AI antibody discovery partnership with Funnel Biosciences worth up to $2.16 billion
Third Rock Ventures has entered a potentially $2.16 billion AI-enabled antibody discovery collaboration with China's Funnel Biosciences, combining epitope-guided molecular design with multiple venture-selected drug targets.

nuaxia
Nov 112 min read


AstraZeneca acquires Omniose to expand bacterial conjugate vaccine technology
AstraZeneca has completed its acquisition of US vaccine technology company Omniose, adding a proprietary bacterial bioconjugation platform to strengthen development of vaccines against serious infections and antimicrobial-resistant pathogens.

nuaxia
Nov 112 min read


BDR Pharma agrees to acquire controlling stake in Acme's oral formulations business
BDR Pharma has agreed to acquire a controlling interest in Acme's oral solid formulations business from shareholders led by PAG, strengthening its capabilities in specialist formulations while leaving Acme's sterile injectables operation outside the transaction.

nuaxia
Nov 102 min read


Abeona acquires Phase III-ready ABO-801 drug assets from Ellodi in transaction worth up to $80 million plus royalties
Abeona Therapeutics has acquired the Phase III-ready eosinophilic oesophagitis candidate ABO-801 from Ellodi Pharmaceuticals in a share-based asset transaction with regulatory and commercial milestones, alongside a separate $30 million financing agreement.

nuaxia
Nov 102 min read


argenx agrees to acquire Unnatural Products for up to $1.15 billion to expand peptide drug discovery
argenx has agreed to acquire macrocyclic peptide specialist Unnatural Products in a transaction worth up to $1.15 billion, combining a substantial upfront payment with development-dependent milestones to expand beyond antibody therapeutics.

nuaxia
Nov 102 min read


Dipharma acquires UK rare-disease medicines distributor LogixX Pharma
Dipharma Group has acquired longstanding UK partner LogixX Pharma, converting a decade-long rare-disease medicines distribution relationship into a directly owned British commercial operation.

nuaxia
Nov 92 min read


Avanzanite licenses Zemcelpro stem cell therapy commercialisation rights across 32 European countries
Avanzanite has secured exclusive European commercialisation rights to Cordex Biologics' conditionally authorised cord-blood stem cell therapy Zemcelpro, covering 32 countries under new licensing and supply agreements.

nuaxia
Nov 92 min read
bottom of page